TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01262170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CigRx Lozenge
Description: lozenge made of dietary supplements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Lozenge
Description: lozenge made of compressed cured tobacco extract
Study: NCT00819377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: inhaled milrinone 5 mg (as for the injectable solution)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 5 ml normal saline by inhalation over 15 min
Study: NCT00534378

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Midazolam
Description: The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
Study: NCT00795834

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High polyphenol beverage
Description: Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)
Study: NCT01170598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
Study: NCT01768104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESTD
Description: 1. A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~2. Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~3. Dissection was done along the margin of the tumor.~4. After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~5. Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors... Endoscopy 2012; 44: 231-235)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS
Description: 1. General anesthesia with double lumen intubation.~2. Three to four cameras or working ports are placed over the chest wall.~3. After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~4. The mass is exposed after the overlying muscle is split longitudinally.~5. The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~6. The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)
Study: NCT04251780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment of Hyperaldosteronism
Description: Surgery of an Aldosterone-producing adenoma
Study: NCT03761381

Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography (OCTA) Imaging
Description: Optical coherence tomography is a non-invasive imaging technology that provides cross-sectional images of tissues in micron-scale resolution. The angiography component of this device allows for evaluation of blood vessel and blood flow changes in the eye. The Solix device with AngioVue software will be used to detect these blood vessel and flow changes as well as protein deposits in the retinal layers.

Intervention type: DEVICE
Intervention: Noninvasive Retinal Amyloid Imaging (NRAI)
Description: The Spectralis will be used for NRAI. This system uses a special light source and optical filters to detect fluorescence of amyloid proteins in the eye.

Intervention type: DEVICE
Intervention: Noninvasive Retinal Amyloid Imaging (NRAI)
Description: The Spectralis will be used for NRAI. This system uses a special light source and optical filters to detect fluorescence of amyloid proteins in the eye.
Study: NCT03315208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Description: The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based psychological intervention designed to be applied across anxiety, depressive, and other disorders in which emotion dysregulation is central. The UP targets shared temperamental vulnerabilities to emotional disorders through emotion-focused CBT strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
Study: NCT00405587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX4032
Description: Oral capsules administered BID
Study: NCT02829463

Intervention type: RADIATION
Intervention: Magnetic resonance imaging
Description: 3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.

Intervention type: RADIATION
Intervention: Magnetic resonance imaging
Description: 3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
Study: NCT01280214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
Study: NCT00499018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclofosfamide
Description: 1200 mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclofosfamide
Description: 1200 mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicina
Description: 70 mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicina
Description: 70 mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristina
Description: 1,4 mg/m2 (max 2 mg) day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristina
Description: 1,4 mg/m2 (max 2 mg) day 1
Study: NCT00337610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
Description: Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
Description: Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
Study: NCT01861041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heavy Bupivacaine
Description: 7,5 mg intrathecal hyperbaric bupivacain,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isobaric Bupivacaine
Description: 7.5 mg intratecal isobaric bupivacain
Study: NCT03528304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Contingency management (CM) is a behavioral intervention that uses gift cards, prizes, or access to privileges to reinforce specific healthy behaviors and lifestyle changes. CM has been used successfully for a range of addictive behaviors, including cigarette smoking and heroin, cocaine, methamphetamine, and other illicit substance use, as well as for reducing psychiatric problems and HIV risk. CM has great potential for treating smoking and overweight/obesity, as it reinforces both short- and long-term behaviors. This is important because both smoking cessation and weight loss are highly prone to short-term relapse,
Study: NCT00499018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristina
Description: 1,4 mg/m2 (max 2 mg) day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristina
Description: 1,4 mg/m2 (max 2 mg) day 1
Study: NCT01371799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug
Description: 4mg and 8mg Study drug
Study: NCT00499018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg day g 1-5
Study: NCT03817541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edmon (reg), BBraun
Description: exhaled propofol will be compared With plasma propofol values

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edmon (reg), BBraun
Description: exhaled propofol will be compared With plasma propofol values
Study: NCT00499018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg day g 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg day g 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg day g 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg day +1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg day +1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg day +1
Study: NCT03086044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir
Description: 2 weeks of treatment beginning on the day of transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir
Description: 2 weeks of treatment beginning on the day of transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
Study: NCT03701373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 maintenance
Description: S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Observation without anti-tumor treatment
Study: NCT03803176

Intervention type: PROCEDURE
Intervention: Open Flap Debridement
Description: Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
Study: NCT00499018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 8 mg/m2/days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 8 mg/m2/days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C
Description: 2000 mg/m2/12h day 1 - 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C
Description: 2000 mg/m2/12h day 1 - 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenograstim
Description: 5 μg/Kg/days +2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenograstim
Description: 5 μg/Kg/days +2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300 mg/m2 day -7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300 mg/m2 day -7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C
Description: 200 mg/m2/12 days -6,-5,-4,-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C
Description: 200 mg/m2/12 days -6,-5,-4,-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: 100 mg/m2/12h days -6,-5,-4,-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: 100 mg/m2/12h days -6,-5,-4,-3

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: PBSC Reinfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: PBSC Reinfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclofosfamide
Description: 750 mg/m2 day 1
Study: NCT02251366

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physician-guided diagnostic
Description: NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
Study: NCT02652611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SI Screw Removal Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-screw removal treatment (non-operative management)
Study: NCT00499018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclofosfamide
Description: 750 mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicina
Description: 50 mg/m2 day 1
Study: NCT01633567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Targeted Cessation Program
Description: The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Targeted Cessation Program
Description: Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
Study: NCT04027842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prewarming
Description: In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
Study: NCT00499018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicina
Description: 50 mg/m2 day 1
Study: NCT03898856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer
Description: 125 mg tablets taken by mouth twice daily for 28 days

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic tests for cause of chronic diarrhea
Description: Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
Study: NCT00724789

Intervention type: DRUG
Intervention: ganirelix
Description: Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy

Intervention type: DRUG
Intervention: GnRH agonist
Description: Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
Study: NCT03949205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Extension Isometric Training
Description: The leg extension isometric exercise will be performed tree times a week , in four 2 min bouts of isometric contraction, at a intensity of 30% of maximal voluntary contraction and an interval of two minutes between bouts.
Study: NCT04974112

Intervention type: OTHER
Intervention: Apply SGA and NRS2002
Description: Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information

Intervention type: OTHER
Intervention: Apply SGA and NRS2002
Description: Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information

Intervention type: OTHER
Intervention: Apply SGA and NRS2002
Description: Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information

Intervention type: OTHER
Intervention: Apply SGA and NRS2002
Description: Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information

Intervention type: OTHER
Intervention: Apply SGA and NRS2002
Description: Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information

Intervention type: OTHER
Intervention: Apply SGA and NRS2002
Description: Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information
Study: NCT02734979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biobridge and lymph node transfer
Description: Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
Study: NCT02826031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DICL-SR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DICL-SR
Study: NCT03964155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sample
Description: After an exposure duration of at least 12 hours, a sample of directly-aspirated, undiluted pulmonary edema fluid will be collected concurrently with AnaConDa-S® filter collection.
Study: NCT00746642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mellitor device for glucose measurement
Description: Glucose measurement using Mellitor device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mellitor device for glucose measurement
Description: Glucose measurement using Mellitor device
Study: NCT02089633

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PACOX
Description: Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
Study: NCT03066674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie group
Description: Mobilization for lumbar spine,TENS,Exercises,Postural education ,Home exercises program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: TENS,Exercises,Postural education ,Home exercises program.
Study: NCT00740142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-ornithine-L-aspartate and lactulose
Description: L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo and lactulose
Description: placebo 3 times a day for 7 days
Study: NCT03128346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Transversus Plane Block
Description: The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: IV, Hydromorphone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone Hydrochloride
Description: IV, Hydromorphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Oral Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Oral acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Oral acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: IV, fentanyl